Trial Profile
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 03 Nov 2017 Status changed from active, no longer recruiting to completed.
- 28 Oct 2017 Results of immunological profile changes before, at 6-months and 12-months post-BAF312 treatment presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis